Do FADS genotypes enhance our knowledge about fatty acid related phenotypes?

Clinical Nutrition

Volumn 29, Issue 3, 2010, Pages 277-287

  Lattka, Eva ^a   Illig, Thomas ^a   Heinrich, Joachim ^a   Koletzko, Berthold ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DESATURASE; ACYL COENZYME A DESATURASE 1; ACYL COENZYME A DESATURASE 2; LINOLEOYL COENZYME A DESATURASE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; UNCLASSIFIED DRUG; DELTA-5 FATTY ACID DESATURASE; FADS2 PROTEIN, HUMAN; FADS3 PROTEIN, HUMAN; FATTY ACID; UNSATURATED FATTY ACID;

ATOPY; BRAIN DEVELOPMENT; COGNITIVE DEVELOPMENT; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; ENZYME ACTIVITY; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HUMAN; INTELLIGENCE; LIPID METABOLISM; LIPOGENESIS; MENTAL DEVELOPMENT; METABOLIC SYNDROME X; METABOLITE; PROTEIN LIPID INTERACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VISUAL SYSTEM FUNCTION; ADULT; ANIMAL; CHILD; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; INFANT; METABOLISM; MULTIGENE FAMILY; PHENOTYPE;

ADULT; ANIMALS; CHILD; FATTY ACID DESATURASES; FATTY ACIDS; FATTY ACIDS, UNSATURATED; GENOTYPE; HUMANS; INFANT; MULTIGENE FAMILY; PHENOTYPE; POLYMORPHISM, GENETIC; STEAROYL-COA DESATURASE;

EID: 77953539296     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2009.11.005     Document Type: Review

References (143)

1. Beblo S., Reinhardt H., Demmelmair H., Muntau A.C., Koletzko B. Effect of fish oil supplementation on fatty acid status, coordination, and fine motor skills in children with phenylketonuria. J Pediatr 2007, 150:479-484.
2. Koletzko B., Cetin I., Brenna J.T. Dietary fat intakes for pregnant and lactating women. Br J Nutr 2007, 98:873-877.
3. Muskiet F.A., Kemperman R.F. Folate and long-chain polyunsaturated fatty acids in psychiatric disease. J Nutr Biochem 2006, 17:717-727.
4. Maes M., Smith R., Christophe A., Cosyns P., Desnyder R., Meltzer H. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 1996, 38:35-46.
5. Nakada T., Kwee I.L., Ellis W.G. Membrane fatty acid composition shows delta-6-desaturase abnormalities in Alzheimer's disease. Neuroreport 1990, 1:153-155.
6. Das U.N. Essential fatty acid metabolism in patients with essential hypertension, diabetes mellitus and coronary heart disease. Prostaglandins Leukot Essent Fatty Acids 1995, 52:387-391.
7. van Doormaal J.J., Muskiet F.A., van Ballegooie E., Sluiter W.J., Doorenbos H. The plasma and erythrocyte fatty acid composition of poorly controlled, insulin-dependent (type I) diabetic patients and the effect of improved metabolic control. Clin Chim Acta 1984, 144:203-212.
8. Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 2003, 14:15-19.
9. Leaf A. Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids. Fundam Clin Pharmacol 2006, 20:525-538.
10. Glew R.H., Okolie H., Huang Y.S., Chuang L.T., Suberu O., Crossey M., et al. Abnormalities in the fatty-acid composition of the serum phospholipids of stroke patients. J Natl Med Assoc 2004, 96:826-832.
11. Goldring M.B., Berenbaum F. The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop 2004, S37-S46.
12. Duchen K., Bjorksten B. Polyunsaturated n-3 fatty acids and the development of atopic disease. Lipids 2001, 36:1033-1042.
13. Kompauer I., Demmelmair H., Koletzko B., Bolte G., Linseisen J., Heinrich J. Association of fatty acids in serum phospholipids with hay fever, specific and total immunoglobulin E. Br J Nutr 2005, 93:529-535.
14. Trak-Fellermeier M.A., Brasche S., Winkler G., Koletzko B., Heinrich J. Food and fatty acid intake and atopic disease in adults. Eur Respir J 2004, 23:575-582.
15. Nakamura M.T., Nara T.Y. Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. Annu Rev Nutr 2004, 24:345-376.
16. Krauss-Etschmann S., Shadid R., Campoy C., Hoster E., Demmelmair H., Jimenez M., et al. Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial. Am J Clin Nutr 2007, 85:1392-1400.
17. Koletzko B., Demmelmair H., Schaeffer L., Illig T., Heinrich J. Genetically determined variation in polyunsaturated fatty acid metabolism may result in different dietary requirements. Nestle Nutr Workshop Ser Pediatr Program 2008, 62:35-49.
18. Dobbing J. The later growth of the brain and its vulnerability. Pediatrics 1974, 53:2-6.
19. Koletzko B., Lien E., Agostoni C., Bohles H., Campoy C., Cetin I., et al. The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat Med 2008, 36:5-14.
20. Koletzko B., Larque E., Demmelmair H. Placental transfer of long-chain polyunsaturated fatty acids (LC-PUFA). J Perinat Med 2007, 35(Suppl. 1):S5-S11.
21. Larque E., Demmelmair H., Klingler M., De Jonge S., Bondy B., Koletzko B. Expression pattern of fatty acid transport protein-1 (FATP-1), FATP-4 and heart-fatty acid binding protein (H-FABP) genes in human term placenta. Early Hum Dev 2006, 82:697-701.
22. Koletzko B., Agostoni C., Carlson S.E., Clandinin T., Hornstra G., Neuringer M., et al. Long chain polyunsaturated fatty acids (LC-PUFA) and perinatal development. Acta Paediatr 2001, 90:460-464.
23. Forsyth J.S., Willatts P., Agostoni C., Bissenden J., Casaer P., Boehm G. Long chain polyunsaturated fatty acid supplementation in infant formula and blood pressure in later childhood: follow up of a randomised controlled trial. BMJ 2003, 326:953.
24. Cho H.P., Nakamura M.T., Clarke S.D. Cloning, expression, and nutritional regulation of the mammalian delta-6 desaturase. J Biol Chem 1999, 274:471-477.
25. Cho H.P., Nakamura M., Clarke S.D. Cloning, expression, and fatty acid regulation of the human delta-5 desaturase. J Biol Chem 1999, 274:37335-37339.
26. de Antueno R.J., Knickle L.C., Smith H., Elliot M.L., Allen S.J., Nwaka S., et al. Activity of human delta5 and delta6 desaturases on multiple n-3 and n-6 polyunsaturated fatty acids. FEBS Lett 2001, 509:77-80.
27. Voss A., Reinhart M., Sankarappa S., Sprecher H. The metabolism of 7,10,13,16,19-docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in rat liver is independent of a 4-desaturase. J Biol Chem 1991, 266:19995-20000.
28. Geiger M., Mohammed B.S., Sankarappa S., Sprecher H. Studies to determine if rat liver contains chain-length-specific acyl-CoA 6-desaturases. Biochim Biophys Acta 1993, 1170:137-142.
29. D'andrea S., Guillou H., Jan S., Catheline D., Thibault J.N., Bouriel M., et al. The same rat delta6-desaturase not only acts on 18- but also on 24-carbon fatty acids in very-long-chain polyunsaturated fatty acid biosynthesis. Biochem J 2002, 364:49-55.
30. Williard D.E., Nwankwo J.O., Kaduce T.L., Harmon S.D., Irons M., Moser H.W., et al. Identification of a fatty acid delta6-desaturase deficiency in human skin fibroblasts. J Lipid Res 2001, 42:501-508.
31. Marzo I., Alava M.A., Pineiro A., Naval J. Biosynthesis of docosahexaenoic acid in human cells: evidence that two different delta 6-desaturase activities may exist. Biochim Biophys Acta 1996, 1301:263-272.
32. Marzo I., Pineiro A., Naval J. Loss of delta6-desaturase activity leads to impaired docosahexaenoic acid synthesis in Y-79 retinoblastoma cells. Prostaglandins Leukot Essent Fatty Acids 1998, 59:293-297.
33. Marquardt A., Stohr H., White K., Weber B.H. cDNA cloning, genomic structure, and chromosomal localization of three members of the human fatty acid desaturase family. Genomics 2000, 66:175-183.
34. Park W.J., Kothapalli K.S., Reardon H.T., Kim L.Y., Brenna J.T. Novel fatty acid desaturase 3 (FADS3) transcripts generated by alternative splicing. Gene 2009.
35. Guillou H., Rioux V., Catheline D., Thibault J.N., Bouriel M., Jan S., et al. Conversion of hexadecanoic acid to hexadecenoic acid by rat delta 6-desaturase. J Lipid Res 2003, 44:450-454.
36. Rodriguez A., Sarda P., Nessmann C., Boulot P., Leger C.L., Descomps B. Delta6- and delta5-desaturase activities in the human fetal liver: kinetic aspects. J Lipid Res 1998, 39:1825-1832.
37. Guillou H., D'andrea S., Rioux V., Jan S., Legrand P. The surprising diversity of delta6-desaturase substrates. Biochem Soc Trans 2004, 32:86-87.
38. Park W.J., Kothapalli K.S., Lawrence P., Tyburczy C., Brenna J.T. An alternate pathway to long-chain polyunsaturates: the FADS2 gene product delta8-desaturates 20:2n-6 and 20:3n-3. J Lipid Res 2009, 50:1195-1202.
39. Stoffel W., Holz B., Jenke B., Binczek E., Gunter R.H., Kiss C., et al. Delta6-desaturase (FADS2) deficiency unveils the role of omega3- and omega6-polyunsaturated fatty acids. EMBO J 2008, 27:2281-2292.
40. Stroud C.K., Nara T.Y., Roqueta-Rivera M., Radlowski E.C., Lawrence P., Zhang Y., et al. Disruption of FADS2 gene in mice impairs male reproduction and causes dermal and intestinal ulceration. J Lipid Res 2009.
41. Schaeffer L., Gohlke H., Müller M., Heid I.M., Palmer L.J., Kompauer I., et al. Common genetic variants of the FADS1-FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 2006, 15:1745-1756.
42. Malerba G., Schaeffer L., Xumerle L., Klopp N., Trabetti E., Biscuola M., et al. SNPs of the FADS gene cluster are associated with polyunsaturated fatty acids in a cohort of patients with cardiovascular disease. Lipids 2008, 43:289-299.
43. Rzehak P., Heinrich J., Klopp N., Schaeffer L., Hoff S., Wolfram G., et al. Evidence for an association between genetic variants of the fatty acid desaturase 1 fatty acid desaturase 2 (FADS1-FADS2) gene cluster and the fatty acid composition of erythrocyte membranes. Br J Nutr 2008, 1-7.
44. Xie L., Innis S.M. Genetic variants of the FADS1-FADS2 gene cluster are associated with altered (n-6) and (n-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. J Nutr 2008, 138:2222-2228.
45. Innis S.M. Polyunsaturated fatty acids in human milk: an essential role in infant development. Adv Exp Med Biol 2004, 554:27-43.
46. Koletzko B., Braun M. Arachidonic acid and early human growth: is there a relation?. Ann Nutr Metab 1991, 35:128-131.
47. Helland I.B., Saugstad O.D., Smith L., Saarem K., Solvoll K., Ganes T., et al. Similar effects on infants of n-3 and n-6 fatty acids supplementation to pregnant and lactating women. Pediatrics 2001, 108:E82.
48. Helland I.B., Smith L., Saarem K., Saugstad O.D., Drevon C.A. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. Pediatrics 2003, 111:e39-e44.
49. Helland I.B., Smith L., Blomen B., Saarem K., Saugstad O.D., Drevon C.A. Effect of supplementing pregnant and lactating mothers with n-3 very-long-chain fatty acids on children's IQ and body mass index at 7 years of age. Pediatrics 2008, 122:e472-e479.
50. Jensen C.L., Voigt R.G., Prager T.C., Zou Y.L., Fraley J.K., Rozelle J.C., et al. Effects of maternal docosahexaenoic acid intake on visual function and neurodevelopment in breastfed term infants. Am J Clin Nutr 2005, 82:125-132.
51. Innis S.M., Gilley J., Werker J. Are human milk long-chain polyunsaturated fatty acids related to visual and neural development in breast-fed term infants?. J Pediatr 2001, 139:532-538.
52. Agostoni C., Marangoni F., Giovannini M., Riva E., Galli C. Long-chain polyunsaturated fatty acids, infant formula, and breastfeeding. Lancet 1998, 352:1703-1704.
53. Fidler N., Sauerwald T., Pohl A., Demmelmair H., Koletzko B. Docosahexaenoic acid transfer into human milk after dietary supplementation: a randomized clinical trial. J Lipid Res 2000, 41:1376-1383.
54. Agostoni C., Marangoni F., Grandi F., Lammardo A.M., Giovannini M., Riva E., et al. Earlier smoking habits are associated with higher serum lipids and lower milk fat and polyunsaturated fatty acid content in the first 6 months of lactation. Eur J Clin Nutr 2003, 57:1466-1472.
55. Makrides M., Neumann M.A., Gibson R.A. Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition. Eur J Clin Nutr 1996, 50:352-357.
56. Gibson R.A., Neumann M.A., Makrides M. Effect of increasing breast milk docosahexaenoic acid on plasma and erythrocyte phospholipid fatty acids and neural indices of exclusively breast fed infants. Eur J Clin Nutr 1997, 51:578-584.
57. Marangoni F., Agostoni C., Lammardo A.M., Bonvissuto M., Giovannini M., Galli C., et al. Polyunsaturated fatty acids in maternal plasma and in breast milk. Prostaglandins Leukot Essent Fatty Acids 2002, 66:535-540.
58. Smit E.N., Martini I.A., Mulder H., Boersma E.R., Muskiet F.A. Estimated biological variation of the mature human milk fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 2002, 66:549-555.
59. Yuhas R., Pramuk K., Lien E.L. Human milk fatty acid composition from nine countries varies most in DHA. Lipids 2006, 41:851-858.
60. Rodriguez-Cruz M., Tovar A.R., Palacios-Gonzalez B., Del Prado M., Torres N. Synthesis of long-chain polyunsaturated fatty acids in lactating mammary gland: role of delta5 and delta6 desaturases, SREBP-1, PPARalpha, and PGC-1. J Lipid Res 2006, 47:553-560.
61. Innis S.M. Essential fatty acid transfer and fetal development. Placenta 2005, 26(Suppl. A):S70-S75.
62. Elias S.L., Innis S.M. Infant plasma trans, n-6, and n-3 fatty acids and conjugated linoleic acids are related to maternal plasma fatty acids, length of gestation, and birth weight and length. Am J Clin Nutr 2001, 73:807-814.
63. Innis S.M., Friesen R.W. Essential n-3 fatty acids in pregnant women and early visual acuity maturation in term infants. Am J Clin Nutr 2008, 87:548-557.
64. Gieger C., Geistlinger L., Altmaier E., Hrabé de Angelis M., Kronenberg F., Meitinger T., et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet 2008, 4:e1000282.
65. Willer C.J., Sanna S., Jackson A.U., Scuteri A., Bonnycastle L.L., Clarke R., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008, 40:161-169.
66. Kathiresan S., Melander O., Guiducci C., Surti A., Burtt N.P., Rieder M.J., et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008, 40:189-197.
67. Aulchenko Y.S., Ripatti S., Lindqvist I., Boomsma D., Heid I.M., Pramstaller P.P., et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009, 41:47-55.
68. Kathiresan S., Willer C.J., Peloso G.M., Demissie S., Musunuru K., Schadt E.E., et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009, 41:56-65.
69. Sabatti C., Service S.K., Hartikainen A.L., Pouta A., Ripatti S., Brodsky J., et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet 2009, 41:35-46.
70. Schadt E.E., Molony C., Chudin E., Hao K., Yang X., Lum P.Y., et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol 2008, 6:e107.
71. Phillipson B.E., Rothrock D.W., Connor W.E., Harris W.S., Illingworth D.R. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 1985, 312:1210-1216.
72. Dixon A.L., Liang L., Moffatt M.F., Chen W., Heath S., Wong K.C., et al. A genome-wide association study of global gene expression. Nat Genet 2007, 39:1202-1207.
73. Tanaka T., Shen J., Abecasis G.R., Kisialiou A., Ordovas J.M., Guralnik J.M., et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI study. PLoS Genet 2009, 5:e1000338.
74. Fruchart J.C., Duriez P., Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999, 10:245-257.
75. Hertz R., Bishara-Shieban J., Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995, 270:13470-13475.
76. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., Heyman R.A., Briggs M., Deeb S., et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996, 15:5336-5348.
77. Vu-Dac N., Schoonjans K., Laine B., Fruchart J.C., Auwerx J., Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994, 269:31012-31018.
78. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J.C., Staels B., et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995, 96:741-750.
79. Guerin M., Bruckert E., Dolphin P.J., Turpin G., Chapman M.J. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996, 16:763-772.
80. Uauy R., Mena P., Wegher B., Nieto S., Salem N. Long chain polyunsaturated fatty acid formation in neonates: effect of gestational age and intrauterine growth. Pediatr Res 2000, 47:127-135.
81. Malcolm C.A., McCulloch D.L., Montgomery C., Shepherd A., Weaver L.T. Maternal docosahexaenoic acid supplementation during pregnancy and visual evoked potential development in term infants: a double blind, prospective, randomised trial. Arch Dis Child Fetal Neonatal Ed 2003, 88:F383-F390.
82. Dunstan J.A., Mori T.A., Barden A., Beilin L.J., Taylor A.L., Holt P.G., et al. Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. J Allergy Clin Immunol 2003, 112:1178-1184.
83. Oken E., Wright R.O., Kleinman K.P., Bellinger D., Amarasiriwardena C.J., Hu H., et al. Maternal fish consumption, hair mercury, and infant cognition in a U.S. cohort. Environ Health Perspect 2005, 113:1376-1380.
84. Hibbeln J.R., Davis J.M., Steer C., Emmett P., Rogers I., Williams C., et al. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet 2007, 369:578-585.
85. Carnielli V.P., Wattimena D.J., Luijendijk I.H., Boerlage A., Degenhart H.J., Sauer P.J. The very low birth weight premature infant is capable of synthesizing arachidonic and docosahexaenoic acids from linoleic and linolenic acids. Pediatr Res 1996, 40:169-174.
86. 13C content. J Pediatr Gastroenterol Nutr 1995, 21:31-36.
87. Salem N., Wegher B., Mena P., Uauy R. Arachidonic and docosahexaenoic acids are biosynthesized from their 18-carbon precursors in human infants. Proc Natl Acad Sci USA 1996, 93:49-54.
88. Sauerwald T.U., Hachey D.L., Jensen C.L., Chen H., Anderson R.E., Heird W.C. Intermediates in endogenous synthesis of C22:6 omega 3 and C20:4 omega 6 by term and preterm infants. Pediatr Res 1997, 41:183-187.
89. Jorgensen M.H., Hernell O., Hughes E., Michaelsen K.F. Is there a relation between docosahexaenoic acid concentration in mothers' milk and visual development in term infants?. J Pediatr Gastroenterol Nutr 2001, 32:293-296.
90. Anderson J.W., Johnstone B.M., Remley D.T. Breast-feeding and cognitive development: a meta-analysis. Am J Clin Nutr 1999, 70:525-535.
91. Lucas A., Morley R., Cole T.J., Lister G., Leeson-Payne C. Breast milk and subsequent intelligence quotient in children born preterm. Lancet 1992, 339:261-264.
92. Der G., Batty G.D., Deary I.J. Effect of breast feeding on intelligence in children: prospective study, sibling pairs analysis, and meta-analysis. BMJ 2006, 333:945.
93. Auestad N., Scott D.T., Janowsky J.S., Jacobsen C., Carroll R.E., Montalto M.B., et al. Visual, cognitive, and language assessments at 39 months: a follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age. Pediatrics 2003, 112:e177-e183.
94. Birch E.E., Garfield S., Castaneda Y., Hughbanks-Wheaton D., Uauy R., Hoffman D. Visual acuity and cognitive outcomes at 4 years of age in a double-blind, randomized trial of long-chain polyunsaturated fatty acid-supplemented infant formula. Early Hum Dev 2007, 83:279-284.
95. Singhal A., Morley R., Cole T.J., Kennedy K., Sonksen P., Isaacs E., et al. Infant nutrition and stereoacuity at age 4-6 y. Am J Clin Nutr 2007, 85:152-159.
96. Gibson R.A., Chen W., Makrides M. Randomized trials with polyunsaturated fatty acid interventions in preterm and term infants: functional and clinical outcomes. Lipids 2001, 36:873-883.
97. Caspi A., Williams B., Kim-Cohen J., Craig I.W., Milne B.J., Poulton R., et al. Moderation of breastfeeding effects on the IQ by genetic variation in fatty acid metabolism. Proc Natl Acad Sci USA 2007, 104:18860-18865.
98. Brookes K.J., Chen W., Xu X., Taylor E., Asherson P. Association of fatty acid desaturase genes with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006, 60:1053-1061.
99. Arcos-Burgos M., Castellanos F.X., Pineda D., Lopera F., Palacio J.D., Palacio L.G., et al. Attention-deficit/hyperactivity disorder in a population isolate: linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11. Am J Hum Genet 2004, 75:998-1014.
100. Ogdie M.N., Fisher S.E., Yang M., Ishii J., Francks C., Loo S.K., et al. Attention deficit hyperactivity disorder: fine mapping supports linkage to 5p13, 6q12, 16p13, and 17p11. Am J Hum Genet 2004, 75:661-668.
101. Ogdie M.N., Macphie I.L., Minassian S.L., Yang M., Fisher S.E., Francks C., et al. A genomewide scan for attention-deficit/hyperactivity disorder in an extended sample: suggestive linkage on 17p11. Am J Hum Genet 2003, 72:1268-1279.
102. Bekaroglu M., Aslan Y., Gedik Y., Deger O., Mocan H., Erduran E., et al. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J Child Psychol Psychiatry 1996, 37:225-227.
103. Chen J.R., Hsu S.F., Hsu C.D., Hwang L.H., Yang S.C. Dietary patterns and blood fatty acid composition in children with attention-deficit hyperactivity disorder in Taiwan. J Nutr Biochem 2004, 15:467-472.
104. Colquhoun I., Bunday S. A lack of essential fatty acids as a possible cause of hyperactivity in children. Med Hypotheses 1981, 7:673-679.
105. Mitchell E.A., Aman M.G., Turbott S.H., Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin Pediatr (Phila) 1987, 26:406-411.
106. Young G.S., Maharaj N.J., Conquer J.A. Blood phospholipid fatty acid analysis of adults with and without attention deficit/hyperactivity disorder. Lipids 2004, 39:117-123.
107. Delion S., Chalon S., Guilloteau D., Besnard J.C., Durand G. Alpha-linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem 1996, 66:1582-1591.
108. Zimmer L., Delion-Vancassel S., Durand G., Guilloteau D., Bodard S., Besnard J.C., et al. Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids. J Lipid Res 2000, 41:32-40.
109. Zimmer L., Delpal S., Guilloteau D., Aioun J., Durand G., Chalon S. Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci Lett 2000, 284:25-28.
110. Zimmer L., Durand G., Guilloteau D., Chalon S. n-3 Polyunsaturated fatty acid deficiency and dopamine metabolism in the rat frontal cortex. Lipids 1999, 34(Suppl.):S251.
111. Zimmer L., Hembert S., Durand G., Breton P., Guilloteau D., Besnard J.C., et al. Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neurosci Lett 1998, 240:177-181.
112. Zimmer L., Vancassel S., Cantagrel S., Breton P., Delamanche S., Guilloteau D., et al. The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. Am J Clin Nutr 2002, 75:662-667.
113. Russell V., de Villiers A., Sagvolden T., Lamm M., Taljaard J. Altered dopaminergic function in the prefrontal cortex, nucleus accumbens and caudate-putamen of an animal model of attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Brain Res 1995, 676:343-351.
114. Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Biobehav Rev 2000, 24:31-39.
115. Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust NZ J Psychiatry 1991, 25:277-283.
116. Levy F., Swanson J.M. Timing, space and ADHD: the dopamine theory revisited. Aust NZ J Psychiatry 2001, 35:504-511.
117. WTCCC Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 2007, 447:661-678.
118. Fallin M.D., Lasseter V.K., Wolyniec P.S., McGrath J.A., Nestadt G., Valle D., et al. Genomewide linkage scan for bipolar-disorder susceptibility loci among Ashkenazi Jewish families. Am J Hum Genet 2004, 75:204-219.
119. Richardson A.J. Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukot Essent Fatty Acids 2004, 70:383-390.
120. Richardson A.J. Long-chain polyunsaturated fatty acids in childhood developmental and psychiatric disorders. Lipids 2004, 39:1215-1222.
121. Turnbull T., Cullen-Drill M., Smaldone A. Efficacy of omega-3 fatty acid supplementation on improvement of bipolar symptoms: a systematic review. Arch Psychiatr Nurs 2008, 22:305-311.
122. De Caterina R., Zampolli A. From asthma to atherosclerosis - 5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med 2004, 350:4-7.
123. Kark J.D., Kaufmann N.A., Binka F., Goldberger N., Berry E.M. Adipose tissue n-6 fatty acids and acute myocardial infarction in a population consuming a diet high in polyunsaturated fatty acids. Am J Clin Nutr 2003, 77:796-802.
124. Baylin A., Campos H. Arachidonic acid in adipose tissue is associated with nonfatal acute myocardial infarction in the central valley of Costa Rica. J Nutr 2004, 134:3095-3099.
125. Baylin A., Kabagambe E.K., Ascherio A., Spiegelman D., Campos H. Adipose tissue alpha-linolenic acid and nonfatal acute myocardial infarction in Costa Rica. Circulation 2003, 107:1586-1591.
126. Lanzmann-Petithory D. Alpha-linolenic acid and cardiovascular diseases. J Nutr Health Aging 2001, 5:179-183.
127. Baylin A., Ruiz-Narvaez E., Kraft P., Campos H. Alpha-linolenic acid, delta6-desaturase gene polymorphism, and the risk of nonfatal myocardial infarction. Am J Clin Nutr 2007, 85:554-560.
128. Martinelli N., Girelli D., Malerba G., Guarini P., Illig T., Trabetti E., et al. FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. Am J Clin Nutr 2008, 88:941-949.
129. Grundy S.M. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006, 47:1093-1100.
130. Surette M.E., Whelan J., Broughton K.S., Kinsella J.E. Evidence for mechanisms of the hypotriglyceridemic effect of n-3 polyunsaturated fatty acids. Biochim Biophys Acta 1992, 1126:199-205.
131. Eritsland J., Seljeflot I., Abdelnoor M., Arnesen H., Torjesen P.A. Long-term effects of n-3 fatty acids on serum lipids and glycaemic control. Scand J Clin Lab Invest 1994, 54:273-280.
132. Krebs J.D., Browning L.M., McLean N.K., Rothwell J.L., Mishra G.D., Moore C.S., et al. Additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women. Int J Obes (Lond) 2006, 30:1535-1544.
133. Kestin M., Clifton P., Belling G.B., Nestel P.J. n-3 Fatty acids of marine origin lower systolic blood pressure and triglycerides but raise LDL cholesterol compared with n-3 and n-6 fatty acids from plants. Am J Clin Nutr 1990, 51:1028-1034.
134. Triboulot C., Hichami A., Denys A., Khan N.A. Dietary (n-3) polyunsaturated fatty acids exert antihypertensive effects by modulating calcium signaling in T cells of rats. J Nutr 2001, 131:2364-2369.
135. Mori T.A. Omega-3 fatty acids and hypertension in humans. Clin Exp Pharmacol Physiol 2006, 33:842-846.
136. Ebbesson S.O., Tejero M.E., Nobmann E.D., Lopez-Alvarenga J.C., Ebbesson L., Romenesko T., et al. Fatty acid consumption and metabolic syndrome components: the GOCADAN study. J Cardiometab Syndr 2007, 2:244-249.
137. Connor W.E., DeFrancesco C.A., Connor S.L. n-3 Fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Ann NY Acad Sci 1993, 683:16-34.
138. Roche H.M., Gibney M.J. Effect of long-chain n-3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol metabolism. Am J Clin Nutr 2000, 71:232S-237S.
139. Weber P., Raederstorff D. Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids - a review. Nutr Metab Cardiovasc Dis 2000, 10:28-37.
140. Wendland E., Farmer A., Glasziou P., Neil A. Effect of alpha linolenic acid on cardiovascular risk markers: a systematic review. Heart 2006, 92:166-169.
141. Barre D.E. The role of consumption of alpha-linolenic, eicosapentaenoic and docosahexaenoic acids in human metabolic syndrome and type 2 diabetes - a mini-review. J Oleo Sci 2007, 56:319-325.
142. Truong H., DiBello J.R., Ruiz-Narvaez E., Kraft P., Campos H., Baylin A. Does genetic variation in the delta6-desaturase promoter modify the association between alpha-linolenic acid and the prevalence of metabolic syndrome?. Am J Clin Nutr 2009, 89:920-925.
143. Lattka E, Eggers S, Moeller G, Heim K, Weber M, Mehta D, et al. A common FADS2 promoter polymorphism increases promoter activity and facilitates binding of transcription factor ELK1. J Lipid Res, in press.